More on MNKD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.75 |
|
|||
| Open | $3.75 | ||||
| 52 Wk High | $2.51 | ||||
| 52 Wk Low | $0.41 | ||||
| Day High | $3.81 | ||||
| Day Low | $3.64 | ||||
| P/E | N/A | ||||
| EPS | $-0.64 | ||||
| Volume | 3,844,284 | ||||
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (A
- MannKind completes randomization in phase 1b study for IPF treatment
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
- Form 8-K MANNKIND CORP For: May 29
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
- MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
- US FDA approves MannKind's inhaled insulin for children
- MannKind gets FDA approval for inhaled insulin in children ages 6 and up
- MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
- Form 8-K MANNKIND CORP For: May 27
Entities mentioned with MNKD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Pre Market Movers | View Related Stories »
- H.C. Wainwright | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
